Sitryx Therapeutics Reports the Initiation of a P-I Study of SIT-011 by Eli Lilly to treat Chronic Autoimmune and Inflammatory Diseases
Shots:
- Sitryx Therapeutics partner Eli Lilly has initiated a P-I clinical trial evaluating SIT-011 in patients with chronic autoimmune & inflammatory diseases
- SIT-011 is the first among the programs from the agreement with Eli Lilly to enter clinical evaluations. Moreover, with this trial, Eli Lilly has exercised its option to an exclusive worldwide license to develop & commercialize SIT-011
- In Mar 2020, Sitryx signed an exclusive global licensing & research collaboration agreement with Eli Lilly under which Sitryx would receive an up front payment of $50M, $10M as equity investment, undisclosed double-digit milestone payments & is eligible to receive additional development & commercial milestones up to $570M plus tiered royalties
Ref: Globenewswire | Image: Sitryx Therapeutics
Related News:- Lilly Signs a Worldwide License and Research Agreement with Sitryx to Develop New Immunometabolic Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
